May, 2024
May 2024
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Vivek Subbiah: Our editorial on the Mission to Target KRAS in Colorectal Cancer
May 15, 2024, 11:55

Vivek Subbiah: Our editorial on the Mission to Target KRAS in Colorectal Cancer

Vivek Subbiah shared a post on LinkedIn:

“Delighted to share our editorial – just published in American Society of Clinical Oncology (ASCO) – Journal of Clinical Oncology Oncology Practice – JCO-OP
‘Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer.’

Let’s accelerate progress in KRAS targeting together.”

Vivek Subbiah

Read further.
Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.